Analyst Ratings For Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has been analyzed by 14 analysts over the last quarter, showing a range of sentiments from bullish to bearish. The average 12-month price target has increased by 7% to $1172.0. Recent analyst actions include several rating raises and price target increases, reflecting positive sentiment despite a slight revenue decline.
August 02, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received positive sentiment from analysts, with several rating raises and an increase in the average 12-month price target by 7% to $1172.0. Despite a slight revenue decline, the company's strong financial metrics and product pipeline contribute to the optimistic outlook.
The positive sentiment from multiple analysts, including several rating raises and increased price targets, suggests a bullish outlook for Regeneron Pharmaceuticals. The company's strong financial metrics and product pipeline further support this positive sentiment, despite a slight revenue decline.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100